Fig. 6

Anti-tumor activity of 32A9 CAR-T cells. a Schematic diagram of 32A9 CAR in the second generation 4-1BB format. FMC63 CAR is used as a negative control. b Transduction efficiency of 32A9 CAR-T cells and FMC63 CAR-T cells. c LDH release assay to detect the cytotoxicity of 32A9 CAR-T cells. Values represent the mean ± SD, with *p < 0.05 and ***p < 0.001. d ELISA to detect the activation of 32A9 CAR-T cells by measuring IL-2 release. Values represent the mean ± SD, with ***p < 0.001. eIn vivo animal test of 32A9 CAR-T cells on Huh-7 xenograft tumors. Ten million PBMCs or 32A9 CAR-T cells are infused into mice by tail vein injection. The tumor size is measured every other day. Values represent the mean ± SEM, with *p < 0.05. fIn vivo animal test of 32A9 CAR-T cells on Hep3B xenograft tumors. PBS or ten million of FMC63 CAR-T cells or 32A9 CAR-T cells were infused into mice carrying Hep3B xenograft tumors by tail vein injection once a week for 2 weeks. The tumor burdens were quantified by measuring luciferase fluorescence weekly. Values represent the mean ± SEM, with ***p < 0.001